1. Saroglitazar - A novel treatment for non-alcoholic steatohepatitis.
- Author
-
Noorani, Shifa, Ankam, Manasa, Ganesh, C. H. S. V., Banu, Rahnuma, Salome Satya Vani, P., Polarapu, Naveen, Jangra, Sarita, Shaima, K. A., and Bhyan, Bhupinder
- Subjects
- *
NON-alcoholic fatty liver disease , *DRUG side effects , *LIVER function tests , *HYPOGLYCEMIC agents , *LIVER enzymes , *PEROXISOME proliferator-activated receptors - Abstract
Non-alcoholic fatty liver disease (NAFLD) is a form of chronic liver disease, and NAFLD and non-alcoholic steatohepatitis (NASH) are multifactorial diseases that often co-exist with comorbidities like diabetes and cardio-vascular diseases and may lead to an elevated susceptibility to certain type of cancer. Saroglitazar, a novel agonist targeting peroxisome proliferator-activated receptor (PPAR-α/γ), has recently gained FDA approval for the treatment of NASH. Our aim is to evaluate the clinical outcomes of saroglitazar in NASH patients. With a sample size of 55 patients over 6 months, we conducted a prospective observational study at a tertiary care hospital. Clinical data was collected from patients treated with saroglitazar for NASH in combination with other conditions. Our study results found Saroglitazar to be statistically significant with its use in the treatment of non-alcoholic steatohepatitis, having a good impact on lipid profiles and liver function tests (LFT), in both diabetics and non-diabetics. It was found to improve liver enzymes, total bilirubin, total cholesterol, low-density lipid cholesterol, total cholesterol/high-density lipoprotein ratio (TC/HDL ratio) and was not associated with any serious adverse drug reactions. Our study concludes that patients treated with saroglitazar have a significant improvement in lipid profile and liver function when prescribed alone or in combination with other anti-diabetic agents or statins in NASH patients. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF